CNBC featured Paul Aisen of USC’s Alzheimer’s Therapeutic Research Institute, Christian Pike of the USC Leonard Davis School and Darius Lakdawalla of the USC Schaeffer Center on the FDA’s controversial approval of the drug aducanumab for Alzheimer’s.
